HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-14-2010, 05:45 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
GP2 peptide vaccine Phase II

HER-2/neu peptide vaccine appears safe for breast cancer survivors
David Douglas


Last Updated: 2009-12-11 16:17:24 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A novel HER-2/neu peptide (GP2) breast cancer vaccine safely elicits a specific immune response in women who are cancer-free after standard treatment for node-negative HER-2/neu-positive tumors.

"HER2/neu is a protein that is highly expressed in breast cancers and many other malignancies," senior investigator Dr. George E. Peoples told Reuters Health. Peptides from this protein, specifically GP2, "are the point of recognition between cytotoxic T cells and HER2/neu-expressing cancer cells."

The GP2 peptide, he added, "can be used to stimulate the immune system to generate many cancer-killing T cells in a very safe manner."

In a November 18th on-line publication in Cancer, Dr. Peoples of Brooke Army Medical Center, Fort Sam Houston, Texas and colleagues report the first phase I study of the vaccine, the goal of which was to identify the optimal doses of GP2 peptide and adjuvant granulocyte-macrophage-colony stimulating factor (GM-CSF). Eighteen disease-free node-negative breast cancer survivors with all levels of HER-2/neu expression were enrolled.

The first three groups, each containing three women, received 6 monthly doses of 100 mcg, 500 mcg and 1000 mcg of GP2, respectively, with 250 mcg of GM-CSF. Eight patients required a GM-CSF dose reduction because of local reactions. The last nine patients each received 500 mcg of GP2 with 125 mcg of GM-CSF.

Ex vivo, GP2-specific CD8+ T cells rose from a baseline median of 0.4% to a median post-vaccination maximum of 1.1%. The response was greatest among those without pre-existing immunity.

In vivo, delayed type hypersensitivity reaction responses rose from a baseline median of 0 to a median of 27.5 mm. Greater responses were seen in patients without pre-existing immunity and also with the 250 mcg GM-CSF dose. There was also an increase in E75-specific CD8+ T cells.

"We have vaccinated breast cancer patients who have been treated with surgery, chemotherapy, and radiation and, therefore, are disease-free but who are at a high risk for recurrence," continued Dr. Peoples.

"This trial has shown the GP2 vaccine to be safe and capable of raising immunity against HER2/neu, but the real question is whether this immunity will result in a clinical benefit and prevent recurrences in these women."

"To answer this crucial question, a randomized phase II clinical trial has been initiated," he said.

Cancer 2010.
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes

Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"

Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla

Reconstruction: TRAM flap, partial loss, Revision

The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 09:14 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2018, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter